Quick Answer
Amphastar Pharmaceuticals, Inc. reported Gross Profit of $356.06 million for fiscal year 2025.
Amphastar Pharmaceuticals, Inc. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2025 | $356.06M | -4.8% |
| 2024 | $373.86M | +6.5% |
| 2023 | $351.12M | +41.1% |
| 2022 | $248.86M | +24.6% |
| 2021 | $199.74M | +39.3% |
| 2020 | $143.34M | +8.7% |
| 2019 | $131.92M | +23.3% |
| 2018 | $106.98M | +18.2% |
| 2017 | $90.51M | -13.1% |
| 2016 | $104.20M | +34.7% |
| 2015 | $77.35M | +50.9% |
| 2014 | $51.26M | -41.1% |
| 2013 | $86.96M | -3.7% |
| 2012 | $90.30M | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $98.65M | -3.2% | +14.1% |
| June 30, 2025 | $86.49M | -9.1% | +1.5% |
| March 31, 2025 | $85.25M | -5.4% | -16.4% |
| September 30, 2024 | $101.94M | -6.0% | +7.1% |
| June 30, 2024 | $95.17M | +30.8% | +5.6% |
| March 31, 2024 | $90.10M | +22.0% | -16.9% |
| September 30, 2023 | $108.40M | +85.3% | +49.0% |
| June 30, 2023 | $72.74M | +14.8% | -1.5% |
- Amphastar Pharmaceuticals, Inc. showed a decrease of -4.8% in Gross Profit compared to the prior fiscal year.
- Over the 2012–2025 period, Amphastar Pharmaceuticals, Inc.’s gross profit has grown by 294.3% (from $90.30 million to $356.06 million).
- The most recent figure is from Amphastar Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: